PTSD Mobile App for Cancer Survivors

NCT ID: NCT04058795

Last Updated: 2025-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

524 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-24

Study Completion Date

2025-05-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to use a stepped-care approach in treating symptoms of posttraumatic stress disorder (PTSD). The information learned by doing this study may help us to develop some target treatments for PTSD symptoms in survivors of stem cell transplant.

Participants in this study will be randomized to a mobile app or usual care. An assessment will be made after 4 weeks and a determination made of adding more intensive treatment. Participants will be asked to complete a questionnaire 4 times over a period of 6 months, at the time your participation is complete.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Posttraumatic Stress Disorder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer Distress Coach (CaDC)

Participants in this group will get the mHealth CaDC app, which will give them tools based on cognitive behavioral therapy principles to manage their stress.

Group Type EXPERIMENTAL

Cancer Distress Coach (CaDC) App

Intervention Type BEHAVIORAL

an app that provides participants with tools to manage their stress in the moment they experience it.

CaDC and mCoaching

Participants in this group will get both the CaDC app and weekly clinician support.

Group Type EXPERIMENTAL

CaDC + mCoaching

Intervention Type BEHAVIORAL

The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.

mCBT

Participants in this group will get 8-sessions with a therapist to receive cognitive behavioral therapy (CBT).

Group Type EXPERIMENTAL

mCBT

Intervention Type BEHAVIORAL

8 mobile sessions with a therapist to receive cognitive behavioral therapy.

Control

Participants in this group can use mental health services commonly available to all cancer patients at their local medical facility but will not receive access to the CaDC app.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cancer Distress Coach (CaDC) App

an app that provides participants with tools to manage their stress in the moment they experience it.

Intervention Type BEHAVIORAL

CaDC + mCoaching

The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.

Intervention Type BEHAVIORAL

mCBT

8 mobile sessions with a therapist to receive cognitive behavioral therapy.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Completion of autologous or allogeneic HCT 1-5 years previously
* Partial or complete remission (NED), may be receiving chemoprevention
* Absence of severe psychological impairment (eg hospitalization for suicidality)
* Approved for contact by oncologist
* Able and willing to participate in a one-hour baseline interview
* No prior CBT for PTSD
* Owns a smart device with internet and email access
* Able to read and write English
* Significant PTSD symptoms as indicated by at least one of the following two criteria: probable cancer-related PTSD on the PCL5 by using the symptom cluster criteria; subthreshold or partial PTSD symptoms as determined by endorsement of reexperiencing cluster and less than or equal to 1 other symptom cluster
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Duke University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sophia K Smith, PhD, MSW

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Memorial Sloan Kettering

New York, New York, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Fred Hutchinson Cancer Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Smith SK, Manschot C, Kuhn E, Laber E, Somers TJ, Syrjala KL, Applebaum AJ. Assessing the utility of the PC-PTSD-5 as a screening tool among a cancer survivor sample. Cancer. 2024 Dec 1;130(23):4118-4126. doi: 10.1002/cncr.35504. Epub 2024 Aug 14.

Reference Type DERIVED
PMID: 39141666 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00103154

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Deep Brain Stimulation for Refractory PTSD
NCT06705296 RECRUITING PHASE1
Deep Brain Stimulation for Treatment Refractory PTSD
NCT03416894 ACTIVE_NOT_RECRUITING NA